PLXP VS KRBP Stock Comparison

Performance

PLXP
10/100

PLXP returned -96.94% in the last 12 months. Based on the other stocks in its sector with an average return of -31.58%, its performance is below average giving it a grade of 10 of 100.

KRBP
10/100

KRBP returned -74.58% in the last 12 months. Based on SPY's performance of -7.13%, its performance is below average giving it a score of 10 of 100.

Forecast

PLXP
75/100

1 analysts offer 12-month price forecasts for PLXP. Together, they have an average target of 0, the most optimistic forecast put PLXP at 0 within 12-months and the most pessimistic has PLXP at 0.

KRBP

"Forecast" not found for KRBP

Sentiment

PLXP
71/100

PLXP had a bullish sentiment score of 70.81% across Twitter and StockTwits over the last 12 months. It had an average of 9.26 posts, 0.97 comments, and 3.56 likes per day.

KRBP

"Sentiment" not found for KRBP

Technicals

PLXP
10/100

PLXP receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

KRBP
50/100

KRBP receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

PLXP
10/100

PLXP has missed earnings 9 times in the last 20 quarters.

KRBP
19/100

KRBP has missed earnings 3 times in the last 20 quarters.

Profit

PLXP
41/100

Out of the last 20 quarters, PLXP has had 8 profitable quarters and has increased their profits year over year on 6 of them.

KRBP
10/100

Out of the last 17 quarters, KRBP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

PLXP
30/100

PLXP has had a lower than average amount of volatility over the last 12 months giving it a grade of 29 of 100.

KRBP
55/100

KRBP has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

All score calculations are broken down here to help you make more informed investing decisions

PLx Pharma Inc. Common Stock Summary

Nasdaq / PLXP

Healthcare

Drug Manufacturers—Specialty & Generic

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Kiromic BioPharma, Inc. Common Stock Summary

Nasdaq / KRBP

Healthcare

Biotechnology

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Power up your portfolio